Waverly Advisors LLC Purchases 18,722 Shares of Bristol-Myers Squibb (NYSE:BMY)

Waverly Advisors LLC raised its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 140.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 32,099 shares of the biopharmaceutical company's stock after acquiring an additional 18,722 shares during the quarter. Waverly Advisors LLC's holdings in Bristol-Myers Squibb were worth $1,816,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. LaFleur & Godfrey LLC lifted its position in shares of Bristol-Myers Squibb by 3.5% during the 4th quarter. LaFleur & Godfrey LLC now owns 43,551 shares of the biopharmaceutical company's stock valued at $2,463,000 after buying an additional 1,487 shares during the last quarter. Atomi Financial Group Inc. raised its stake in Bristol-Myers Squibb by 78.0% in the 4th quarter. Atomi Financial Group Inc. now owns 12,768 shares of the biopharmaceutical company's stock valued at $722,000 after acquiring an additional 5,593 shares during the period. Simon Quick Advisors LLC lifted its holdings in Bristol-Myers Squibb by 32.2% during the fourth quarter. Simon Quick Advisors LLC now owns 9,031 shares of the biopharmaceutical company's stock valued at $511,000 after purchasing an additional 2,201 shares during the last quarter. Global Trust Asset Management LLC boosted its position in Bristol-Myers Squibb by 50.0% during the fourth quarter. Global Trust Asset Management LLC now owns 1,801 shares of the biopharmaceutical company's stock worth $102,000 after purchasing an additional 600 shares during the period. Finally, Albion Financial Group UT increased its stake in shares of Bristol-Myers Squibb by 54.1% in the fourth quarter. Albion Financial Group UT now owns 1,849 shares of the biopharmaceutical company's stock worth $105,000 after purchasing an additional 649 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of Bristol-Myers Squibb stock in a transaction on Friday, April 25th. The shares were acquired at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the transaction, the executive vice president now directly owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 0.07% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

BMY has been the topic of a number of recent research reports. Argus upgraded shares of Bristol-Myers Squibb to a "hold" rating in a research note on Friday, April 25th. UBS Group dropped their target price on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Jefferies Financial Group reduced their price target on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. William Blair reiterated a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Finally, Citigroup raised their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, Bristol-Myers Squibb has an average rating of "Hold" and a consensus price target of $58.00.

Bristol-Myers Squibb Price Performance

Bristol-Myers Squibb stock traded down $0.15 during mid-day trading on Friday, hitting $46.88. 8,401,343 shares of the company traded hands, compared to its average volume of 13,150,161. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33. The stock has a market cap of $95.40 billion, a price-to-earnings ratio of -10.61, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39. The stock has a fifty day moving average price of $51.79 and a 200-day moving average price of $55.71.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. During the same period in the previous year, the business earned ($4.40) earnings per share. The firm's quarterly revenue was down 5.6% compared to the same quarter last year. On average, equities analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were issued a dividend of $0.62 per share. The ex-dividend date was Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.29%. Bristol-Myers Squibb's dividend payout ratio is 92.88%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.